Triastek, Inc. and Siemens Ltd., China, have agreed to collaborate on digital technologies for the worldwide pharmaceutical business. Triastek's industry-leading 3D printing and digital pharmaceutical technologies, combined with Siemens' worldwide experience in automation and digitalization, should result in unique and disruptive pharmaceutical research and production solutions.
Pharmaceutical companies have been encouraged to modernize their manufacturing processes by adopting continuous manufacturing processes and digital technologies by regulatory agencies such as the US FDA (Food and Drug Administration), the European Medicines Agency and China's NMPA. Triastek is aggressively applying the continuous manufacturing strategy in combination with new digital technologies to simplify and optimize their production processes and products. When these advances are combined with Siemens' digitalization and automation skills, regulatory agencies will be able to meet their goals of reducing pharmaceutical product quality concerns, lowering manufacturing costs, and increasing patient access to high-quality medications.
Triastek and Siemens will collaborate to solve pharmaceutical industry demands and enhance patient outcomes using their respective technology advantages, strengths, and capabilities. Triastek's proprietary pharmaceutical MED® (Melt Extrusion Deposition) 3D printing platform technology for R&D and mass production will accelerate product R&D and facilitate continuous manufacturing approaches, paperless production, real-time product release, equipment, and facility maintenance combined with Siemens' advanced automation and digital technologies. These advances are intended to increase throughput on the manufacturing line while maintaining the greatest product quality.
Finally, Triastek wants to build an intelligent pharmaceutical production center in conjunction with Siemens, where virtual laboratories, smart factories, and digital twin technologies will be integrated into every element of pharmaceutical operations.
Triastek, founded in 2015, is now in the mass manufacturing and commercial development stages. Triastek announced its Era 2.0 Open Strategy in October 2021, which outlines a goal to market its patented MED® 3D printing technology via partnerships with global pharmaceutical firms and suppliers. Triastek delivers digital product R&D and a unique manufacturing platform based on its Open Strategy and cooperation, allowing business partners to use and integrate Triastek technology into their operations, from early medication discovery through commercial production.
"This strategic collaboration has broadened the possibilities of pharmaceutical digitalization. Triastek's MED® 3D printing technology represents a new digital pharmaceutical technology, building the foundation for a digital pharma future. MED® 3D printing represents a novel drug R&D paradigm, from product development through product launch, while introducing new models to manage production and supply. Triastek will make this open platform available to digital technology providers to jointly advance the Pharma 4.0 initiative, serving our greater vision of transforming the pharmaceutical industry's future."
Dr. Senping Cheng, Founder, and CEO of Triastek
Senior Vice President and General Manager of sales region east of digital industries of Siemens Ltd., China, Mr. Jinsong Zhang, also commented on this partnership: "Siemens' strategic cooperation with Triastek builds win-win cooperation of a digital solution provider leader and a 3D printing pharmaceutical leader. Siemens has rich 3D printing experiences and a full spectrum of digital solutions for manufacturing transformation. I believe the fusion of 3D printing technology with pharmaceutical digitalization establishes a new paradigm, which unifies R&D and production, and advances the end-to-end model from demand to delivery. The partnership will help Triastek to accelerate digital ph.